Evonik and DSM select Blair, Nebraska, as manufacturing site for innovative, new omega-3 fatty acids production
Evonik and Royal DSM will locate the commercial-scale production facility for their omega-3 fatty acids from natural marine algae for animal nutrition in Blair, Nebraska. DSM Nutritional Products and Evonik Nutrition & Care plan to invest around US$ 200 million in the facility (US$ 100 million by each party over circa 2 years). The initial annual production capacity will meet roughly 15% of the current total annual demand for EPA and DHA by the salmon aquaculture industry. The facility is expected to come on stream in 2019. Both companies announced in March 2017 the start of a joint venture for this purpose. The establishment of the joint venture, to be named Veramaris® and headquartered in The Netherlands, will be finalized subject to regulatory approvals.
Blair, Nebraska, was chosen as it takes advantage of Evonik’s decades of operational experience for large-scale biotechnology operations. The company has been operating a facility there for the fermentative production of Biolys® - the amino acid L-lysine - for almost 20 years. As an investor and employer Evonik has built a consistent reputation in the local community. The new plant will be located adjacent to Evonik’s current facility on Cargill’s site, with established access to the raw materials needed to produce the high value and pure EPA+DHA omega-3 fatty acid oil.
It will, for the first time, allow for the production of omega-3 fatty acids for animal nutrition without using any fish oil from wild caught fish, a finite resource. Initial applications will be in salmon aquaculture and pet food.
Evonik’s and DSM’s highly concentrated algal oil will enable the animal nutrition industry to keep up with the increasing demand for these two essential omega-3 fatty acids without endangering fish stocks, helping to contribute to healthy animal nutrition as well as to the ecological balance and biodiversity of the oceans.
Until the facility in Blair opens, DSM and Evonik will produce pilot-scale quantities of the algal oil at DSM’s production facility in Kingstree, South Carolina (United States). Customers will be able to receive sizeable quantities of the product for market development while the construction of the new manufacturing plant gets underway.
Veramaris is a 50:50 joint venture of DSM and Evonik for the production of the omega-3 fatty acids EPA and DHA from natural marine algae. Located in Delft, the Netherlands, Veramaris was launched in 2018, because its parent companies shared a vision: to conserve marine life by using a resource the ocean provides – natural marine microalgae. Producing an algal oil rich in the two essential omega-3 fatty acids EPA and DHA through large-scale fermentation at its facility in Blair, Nebraska, USA, Veramaris enables partners along the value chain to become independent from wild-caught fish and meet the growing demand for animal protein responsibly.
This information and any recommendations, technical or otherwise, are presented in good faith and believed to be correct as of the date prepared. Recipients of this information and recommendations must make their own determination as to its suitability for their purposes. VERAMARIS EXPRESSLY DISCLAIMS ANY REPRESENTATIONS AND WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, RELIABILITY, COMPLETENESS, NON-INFRINGEMENT, MERCHANTABILITY AND/OR FITNESS FOR A PARTICULAR PURPOSE (EVEN IF VERAMARIS IS AWARE OF SUCH PURPOSE) WITH RESPECT TO ANY INFORMATION AND RECOMMENDATIONS PROVIDED. IN NO EVENT SHALL VERAMARIS BE LIABLE FOR ANY DAMAGES ARISING FROM OR RELIANCE UPON, OR USE OF, ANY INFORMATION OR RECOMMENDATIONS PROVIDED HEREIN. Reference to any trade names used by other companies is neither a recommendation nor an endorsement of the corresponding product and does not imply that similar products could not be used. Veramaris reserves the right to make any changes to the information and/or recommendations at any time, without prior or subsequent notice.